David Hallal, Executive Vice President, Chief Commercial Officer
David Hallal is Executive Vice President, Chief Commercial Officer of Alexion Pharmaceuticals.
In this position, he
is responsible for all commercial functions in the United States, EMEA, Japan, Latin America, and Australasia.
also oversees Alexion's Global Therapeutic Franchises across all territories, which now include Hematology, Nephrology, and Metabolic Disorders.
in 2006 to build the company's first commercial organization, and led the highly successful U.S. launch of the company's first product, Soliris
® (eculizumab) for PNH and in 2008, as Alexion
expanded its commercial operations, Mr. Hallal
helped to lead the global launch of PNH.
is leading an expanded global team for the launch of Soliris
in its second indication, atypical hemolytic uremic syndrome (aHUS), and preparing the organization to serve patients globally with neurological, metabolic and other life-threatening and ultra-rare disorders.
Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry.
Before joining Alexon in 2006, Mr. Hallal served as Vice President, Sales at OSI Eyetech where he led the launch of a first-in-class anti-VEGF therapy for age-related macular degeneration.
He also spent 13 years with Amgen and Biogen Idec where he held various commercial leadership positions and was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology.
Mr. Hallal holds a BA from the University of New Hampshire.